How do you manage local recurrence of a resected stage III BRAF WT melanoma occurring during or shortly after completion of adjuvant nivolumab?  

Data presented at ASCO 2019 by Carina Owen suggests that with resection alone in this setting, roughly 50-60 percent of patients will develop recurrent disease. Therefore, resection alone is likely insufficient for these patients. If resection of the local recurrence is pursed, neoadjuvant or altern...